TLR3 and neoplasm: This duality underscores the need for careful consideration and monitoring of TLR3 agonists in anti-tumor therapies, as they may shift the inflammatory balance to either drive tumor regression or inadvertently promote tumorigenesis depending on the context and duration of treatment.